S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:DNLI

Denali Therapeutics - DNLI Stock Forecast, Price & News

$38.11
-0.37 (-0.96%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$37.69
$38.85
50-Day Range
$21.38
$38.53
52-Week Range
$20.24
$56.80
Volume
718,433 shs
Average Volume
599,497 shs
Market Capitalization
$4.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$76.29

Denali Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.2% Upside
$76.29 Price Target
Short Interest
Bearish
7.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.66mentions of Denali Therapeutics in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$712,200 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.69) to ($2.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

497th out of 1,117 stocks

Biological Products, Except Diagnostic Industry

74th out of 175 stocks

DNLI stock logo

About Denali Therapeutics (NASDAQ:DNLI) Stock

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Wedbush cut their target price on Denali Therapeutics from $62.00 to $48.00 in a research note on Friday, May 6th. Berenberg Bank started coverage on Denali Therapeutics in a research note on Thursday, June 23rd. They issued a "buy" rating and a $39.00 target price on the stock. Finally, The Goldman Sachs Group dropped their price objective on Denali Therapeutics from $99.00 to $82.00 and set a "buy" rating on the stock in a research report on Tuesday, May 24th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $76.29.

Denali Therapeutics Trading Down 1.0 %

DNLI Stock traded down $0.37 during trading on Friday, reaching $38.11. The stock had a trading volume of 718,434 shares, compared to its average volume of 599,497. Denali Therapeutics has a 52 week low of $20.24 and a 52 week high of $56.80. The stock's 50 day moving average is $31.13 and its two-hundred day moving average is $30.35. The firm has a market cap of $4.70 billion, a PE ratio of -16.59 and a beta of 1.66.

Denali Therapeutics (NASDAQ:DNLI - Get Rating) last posted its earnings results on Monday, August 8th. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.07. Denali Therapeutics had a negative return on equity of 30.06% and a negative net margin of 252.50%. The company had revenue of $52.50 million for the quarter, compared to the consensus estimate of $44.66 million. During the same quarter in the prior year, the company earned ($0.50) earnings per share. Denali Therapeutics's revenue was up 129.3% on a year-over-year basis. On average, research analysts anticipate that Denali Therapeutics will post -2.69 EPS for the current year.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, Director Marc Tessier-Lavigne sold 20,000 shares of the stock in a transaction dated Monday, July 25th. The stock was sold at an average price of $35.61, for a total value of $712,200.00. Following the transaction, the director now owns 1,950,356 shares of the company's stock, valued at $69,452,177.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 12.70% of the stock is owned by corporate insiders.

Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DNLI Stock News Headlines

See More Headlines
Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DNLI Company Calendar

Last Earnings
8/08/2022
Today
8/12/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DNLI
Fax
N/A
Employees
380
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$76.29
High Stock Price Forecast
$111.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
+100.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-290,580,000.00
Net Margins
-252.50%
Pretax Margin
-252.99%

Debt

Sales & Book Value

Annual Sales
$48.66 million
Book Value
$7.17 per share

Miscellaneous

Free Float
107,683,000
Market Cap
$4.70 billion
Optionable
Optionable
Beta
1.66














DNLI Stock - Frequently Asked Questions

Should I buy or sell Denali Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DNLI shares.
View DNLI analyst ratings
or view top-rated stocks.

What is Denali Therapeutics' stock price forecast for 2022?

7 Wall Street analysts have issued 12 month price targets for Denali Therapeutics' stock. Their DNLI share price forecasts range from $39.00 to $111.00. On average, they expect the company's stock price to reach $76.29 in the next twelve months. This suggests a possible upside of 101.5% from the stock's current price.
View analysts price targets for DNLI
or view top-rated stocks among Wall Street analysts.

How have DNLI shares performed in 2022?

Denali Therapeutics' stock was trading at $44.60 at the beginning of the year. Since then, DNLI stock has decreased by 15.1% and is now trading at $37.86.
View the best growth stocks for 2022 here
.

When is Denali Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our DNLI earnings forecast
.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) posted its quarterly earnings results on Monday, August, 8th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.07. The company earned $52.50 million during the quarter, compared to analyst estimates of $44.66 million. Denali Therapeutics had a negative net margin of 252.50% and a negative trailing twelve-month return on equity of 30.06%. The firm's revenue for the quarter was up 129.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.50) EPS.

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Denali Therapeutics own?

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (12.09%), FMR LLC (2.33%), Pictet Asset Management SA (0.83%), Artisan Partners Limited Partnership (0.37%), Candriam S.C.A. (0.26%) and Principal Financial Group Inc. (0.22%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends
.

How do I buy shares of Denali Therapeutics?

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $37.86.

How much money does Denali Therapeutics make?

Denali Therapeutics (NASDAQ:DNLI) has a market capitalization of $4.67 billion and generates $48.66 million in revenue each year. The company earns $-290,580,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis.

How many employees does Denali Therapeutics have?

The company employs 380 workers across the globe.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.denalitherapeutics.com. The company can be reached via phone at (615) 866-8548 or via email at hansen@dnli.com.

This page (NASDAQ:DNLI) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.